Kyrgyzstan vs Sierra Leone: Prevalence rate of hypertension in men aged 30-79
Kyrgyzstan
38.1
in 2019
Sierra Leone
38
in 2019
Kyrgyzstan rank
87th
Sierra Leone rank
88th
Prevalence rate of hypertension in men aged 30-79 over time
- Kyrgyzstan
- Sierra Leone
How they compare
Kyrgyzstan currently reports 38.1 against 38 in Sierra Leone, a difference of 0.1.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Sierra Leone ahead.
Kyrgyzstan ranks 87th and Sierra Leone ranks 88th of 195 countries.
Sierra Leone has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kyrgyzstan | Sierra Leone | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 34.12 | 39.2 | 5.08 | Sierra Leone |
| 2000s | 34.55 | 40.94 | 6.39 | Sierra Leone |
| 2010s | 36.89 | 39.6 | 2.71 | Sierra Leone |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Kyrgyzstan or Sierra Leone?
- Kyrgyzstan, at 38.1 against 38 in Sierra Leone as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Kyrgyzstan and Sierra Leone?
- 0.1, with Kyrgyzstan ahead.
- How many years of comparable data are there for Kyrgyzstan and Sierra Leone?
- 30 years are reported by both, from 1990 to 2019.
- How do Kyrgyzstan and Sierra Leone rank globally for prevalence rate of hypertension in men aged 30-79?
- Kyrgyzstan ranks 87th and Sierra Leone ranks 88th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.